HRQoL is essentially a measure of the impact that a disease has on patients’ quality of life. While there are a number of instruments that assess HRQoL, disease-specific measures are better tailored to patients with a condition, whereas more generic ones enable comparisons with the general population and people with other diseases. However, the inconsistent use of generic and disease-specific HRQoL tools limits the ability to compare results from MS observational studies and clinical trials. Researchers at Erasmus University Rotterdam, in The Netherlands, set out to use generic and disease-specific tools to assess the HRQoL of adult MS patients in Europe.